Discover and Develop drug candidates to support affordable, shorter, safer, and simpler universal drug regimens that can achieve rapid, durable cure regardless of pre-existing drug resistance.
Tuberculosis (TB) remains a leading cause of death from infectious disease worldwide with 1.3 million lives claimed and an estimated 10 million new cases in 2020*.
First-line therapies for TB are antiquated and inadequate, taking six months to cure patients.
The current six-month regimen contributes to high treatment default rates that can lead to increased transmission, drug resistance, and even death.
We are an innovative discovery network of academic, pharmaceutical, governmental, and other organizations, working collaboratively to gain a better understanding of TB’s pathogenesis to design high impact drug candidates.